Headlines about Innospec (NASDAQ:IOSP) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Innospec earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned media coverage about the specialty chemicals company an impact score of 48.1422414300236 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
IOSP has been the subject of a number of research reports. Zacks Investment Research lowered Innospec from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th. ValuEngine upgraded Innospec from a “hold” rating to a “buy” rating in a research note on Thursday, November 9th. KeyCorp restated an “overweight” rating on shares of Innospec in a research note on Thursday, November 9th. Monness Crespi & Hardt cut Innospec from a “buy” rating to a “neutral” rating in a report on Thursday, November 9th. Finally, Johnson Rice upgraded Innospec from a “hold” rating to an “accumulate” rating in a report on Tuesday, November 14th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the company. Innospec currently has a consensus rating of “Hold” and an average price target of $70.50.
Innospec (NASDAQ IOSP) opened at $66.50 on Tuesday. The stock has a market capitalization of $1,573.77, a PE ratio of 18.42 and a beta of 1.07. Innospec has a 1-year low of $54.10 and a 1-year high of $74.75. The company has a quick ratio of 1.35, a current ratio of 2.24 and a debt-to-equity ratio of 0.30.
In related news, CFO Ian Cleminson sold 5,000 shares of the firm’s stock in a transaction dated Thursday, November 30th. The stock was sold at an average price of $71.67, for a total value of $358,350.00. Following the transaction, the chief financial officer now owns 22,997 shares in the company, valued at $1,648,194.99. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, VP Brian Watt sold 440 shares of the firm’s stock in a transaction dated Tuesday, November 21st. The shares were sold at an average price of $70.17, for a total value of $30,874.80. Following the completion of the transaction, the vice president now owns 30,730 shares in the company, valued at approximately $2,156,324.10. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,366 shares of company stock worth $1,743,891. 2.02% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another domain, it was copied illegally and republished in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/02/13/somewhat-positive-press-coverage-somewhat-unlikely-to-affect-innospec-iosp-stock-price.html.
Innospec Company Profile
Innospec Inc is a specialty chemicals company engaged in developing, manufacturing, blending, marketing and supplying of specialty chemicals for use as fuel additives and ingredients for personal care, home care, agrochemical, mining and other applications and oilfield chemicals. The Company operates through four business segments: Fuel Specialties, Performance Chemicals, Oilfield Services and Octane Additives.
Receive News & Ratings for Innospec Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Innospec and related companies with MarketBeat.com's FREE daily email newsletter.